News

Conference Coverage

Novel Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

03/20/2024

Featuring John Allan, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.

At the Lymphoma, Leukemia &...

03/20/2024

Lymphoma, Leukemia & Myeloma Network

News

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL

03/15/2024

Amber Denham

According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...

According to 5-year follow-up...

03/15/2024

Oncology

Conference Coverage

Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia

02/27/2024

Featuring Neil E. Kay, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.

At the Lymphoma, Leukemia &...

02/27/2024

Lymphoma, Leukemia & Myeloma Network

News

Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL

02/05/2024

Amber Denham

Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.

Venetoclax-obinutuzumab achieved...

02/05/2024

Oncology

News

MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy

02/05/2024

Amber Denham

Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...

Measurable residual...

02/05/2024

Oncology

News

CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL

01/24/2024

Amber Denham

CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.

CD19 CAR T-cell therapy achieved...

01/24/2024

Oncology

Conference Coverage

Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment

01/12/2024

Featuring Adrian Wiestner, MD

At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

Conference Coverage

Evaluating Effects of Racial Disparities on the Treatment of Patients With Chronic Lymphocytic Leukemia

12/12/2023

Fetauring Ira L Zackon, MD

At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.

At the 65th ASH Annual Meeting,...

12/12/2023

Oncology

Conference Coverage

Efficacy of Acalabrutinib With or Without Obinutuzumab Among Patients With Treatment-Naive CLL

12/11/2023

Featuring Jeff Sharman, MD

At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...

At the 65th ASH Annual Meeting,...

12/11/2023

Oncology

Conference Coverage

Extended Follow-up of ALPINE Study Confirms Zanubrutinib Yields Progression-Free Survival Benefit vs Ibrutinib for R/R CLL/SLL

12/11/2023

Featuring Jennifer Brown, MD

At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...

At the 65th ASH Annual Meeting,...

12/11/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology